How does Lutathera work to treat gastroenteropancreatic neuroendocrine tumors?

Lutathera (lutetium Lu 177 dotatate), a Lu-177-labeled somatostatin analogue, is a radioactive drug used to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

How It Works:

• Lutathera is a Lu-177-labeled somatostatin analogue, meaning it binds to somatostatin receptors found on GEP-NET cells.
• Once attached, the radioactive component (Lu-177) delivers targeted radiation to the tumor, helping to kill cancer cells while minimizing damage to surrounding healthy tissue.

FDA Approval:

Lutathera was FDA-approved in January 2018 for the treatment of GEP-NETs, a rare group of cancers that develop in the:

• Pancreas
• Stomach
• Intestines
• Colon
• Rectum

It is currently approved for people ages 12 years and older.

See also:

Drug information

• Lutathera Information for Consumers
• Lutathera prescribing info & package insert (for Health Professionals)
• Side Effects of Lutathera (detailed)
• Lutathera user reviews (1)

Related support groups

• Lutathera (1 questions, 4 members)
• Gastroenteropancreatic Neuroendocrine Tumor (1 questions, 3 members)
• Neuroendocrine Carcinoma (1 questions, 6 members)

Medical Disclaimer